nach oben

Indian Journal of Hematology and Blood Transfusion

Erschienen in:

02.01.2017 | Review Article

Consensus in the Management of Multiple Myeloma in India at Myeloma State of the Art 2016 Conference

Erschienen in: Indian Journal of Hematology and Blood Transfusion | Ausgabe 1/2017

Einloggen, um Zugang zu erhalten

Abstract

The science of multiple myeloma (MM) and related plasma cell disorders is rapidly evolving with increased understanding of the disease biology and recent approval of the newer drugs widening the therapeutic armamentarium. Despite multiple international guidelines regarding the management of this disease, the practice of managing MM is not uniform amongst Indian physicians. There are challenges in management which are unique to the Indian patients. This review discusses these challenges and the consensus of the nation-wide experts in dealing with the same. We also briefly highlighted the perspective of international experts as discussed in the Myeloma State of the Art conference held in September 2016 at PGI, Chandigarh. An Indian Myeloma Academic Groupe (IMAGe) group was formed to strengthen the research, create awareness about myeloma and related disorders and form consensus guidelines/ recommendations that can be adapted to the Indian Scenario.

Reddy KS (2015) India’s aspirations for Universal Health coverage. N Engl J Med 373(1):1–5CrossRefPubMed

Wadhera RK, Rajkumar SV (2010) Prevalence of monoclonal gammopathy of undetermined significance: a systematic review. Mayo Clin Proc 85(10):933–942CrossRefPubMedPubMedCentral

Meher Lakshmi Konatam AP, Sadashivudu G (2016) Age of onset of multiple myeloma: a Paradigm shift in Indian patients Indian. J Appl Res 6(10):3

Smith RA, Manassaram-Baptiste D, Brooks D, Doroshenk M, Fedewa S, Saslow D et al (2015) Cancer screening in the United States, 2015: a review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clin 65(1):30–54CrossRefPubMed

Rajkumar SV (2016) Myeloma today: disease definitions and treatment advances. Am J Hematol 91(1):90–100CrossRefPubMedPubMedCentral

Al-Quran SZ, Yang L, Magill JM, Braylan RC, Douglas-Nikitin VK (2007) Assessment of bone marrow plasma cell infiltrates in multiple myeloma: the added value of CD138 immunohistochemistry. Hum Pathol 38(12):1779–1787CrossRefPubMedPubMedCentral

Paiva B, Vidriales MB, Perez JJ, Mateo G, Montalban MA, Mateos MV et al (2009) Multiparameter flow cytometry quantification of bone marrow plasma cells at diagnosis provides more prognostic information than morphological assessment in myeloma patients. Haematologica 94(11):1599–1602CrossRefPubMedPubMedCentral

Rajan AM, Rajkumar SV (2015) Interpretation of cytogenetic results in multiple myeloma for clinical practice. Blood Cancer J 5:e365CrossRefPubMedPubMedCentral

Dimopoulos M, Kyle R, Fermand JP, Rajkumar SV, San Miguel J, Chanan-Khan A et al (2011) Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. Blood 117(18):4701–4705CrossRefPubMed

10.

Facon T (2015) Maintenance therapy for multiple myeloma in the era of novel agents. Hematol Am Soc Hematol Educ Prog 2015:279–285

11.

Moreau P, Attal M, Facon T (2015) Frontline therapy of multiple myeloma. Blood 125(20):3076–3084CrossRefPubMed

12.

Gertz MA, Dingli D (2014) How we manage autologous stem cell transplantation for patients with multiple myeloma. Blood 124(6):882–890CrossRefPubMedPubMedCentral

13.

Dhakal B, Vesole DH, Hari PN (2016) Allogeneic stem cell transplantation for multiple myeloma: is there a future? Bone Marrow Transp 51(4):492–500CrossRef

14.

Kumar L, Raju GM, Ganessan K, Shawgi S, Menon H, Wadhwa J et al (2003) High dose chemotherapy followed by autologous haemopoietic stem cell transplant in multiple myeloma. Natl Med J India 16(1):16–21PubMed

15.

Trivedi M, Martinez S, Corringham S, Medley K, Ball ED (2009) Optimal use of G-CSF administration after hematopoietic SCT. Bone Marrow Transp 43(12):895–908CrossRef

16.

Chen C, Rabea AM, Masih-Khan E, Chu C-M, Kukreti V, Trudel S et al (2011) Central Nervous System (CNS) Involvement with Multiple Myeloma (MM)–Longterm Survival Can Be Achieved with Radiation, Intrathecal (IT) Chemotherapy, and Immunomodulatory Agents (IMiDs). Blood. 118(21):3983

17.

Dimopoulos MA, Sonneveld P, Leung N, Merlini G, Ludwig H, Kastritis E et al (2016) International myeloma Working Group recommendations for the diagnosis and management of myeloma-related renal impairment. J Clin Oncol 34(13):1544–1557CrossRefPubMed

18.

Silbermann R, Roodman GD (2013) Myeloma bone disease: pathophysiology and management. J Bone Oncol 2(2):59–69CrossRefPubMedPubMedCentral

19.

Vesole DH, Oken MM, Heckler C, Greipp PR, Katz MS, Jacobus S et al (2012) Oral antibiotic prophylaxis of early infection in multiple myeloma: a URCC/ECOG randomized phase III study. Leukemia 26(12):2517–2520CrossRefPubMedPubMedCentral

20.

Alemu A, Richards JO, Oaks MK, Thompson MA (2016) Vaccination in multiple myeloma: review of current literature. Clin Lymphoma Myeloma Leuk 16(9):495–502CrossRefPubMed

Titel: Consensus in the Management of Multiple Myeloma in India at Myeloma State of the Art 2016 Conference
Publikationsdatum: 02.01.2017
Erschienen in: Indian Journal of Hematology and Blood Transfusion / Ausgabe 1/2017
Print ISSN: 0971-4502
Elektronische ISSN: 0974-0449
DOI: https://doi.org/10.1007/s12288-016-0773-9

Neu im Fachgebiet Onkologie

16.04.2024 | Maligne primäre ZNS-Tumoren | Nachrichten

Springer Medizin

Consensus in the Management of Multiple Myeloma in India at Myeloma State of the Art 2016 Conference

Abstract

Neu im Fachgebiet Onkologie

Manche Gestagene können das Risiko für Meningeome erhöhen

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Chemotherapie mit Hindernissen

Das Ende der vollständigen axillären Lymphknotendissektion

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2017

Priapism as the Presenting Manifestation of Multiple Myeloma

Retrospective Study of Pegaspargase, Gemicitabine, Oxaliplatin and Dexamethasone (Peg-GemOD) as a First-Line Therapy for Advanced-Stage Extranodal NK/T Cell Lymphoma

Two Cases of NK/T Cell Lymphoma Presenting as Chronic Rhinosinusitis

Intriguing Morphology of IgG/Lambda Secreting Myeloma Cells

Multiple Auer Rod Like Inclusions in Multiple Myeloma

Nanostructural Changes in the Cell Membrane of Gamma-Irradiated Red Blood Cells

Neu im Fachgebiet Onkologie

Manche Gestagene können das Risiko für Meningeome erhöhen

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Chemotherapie mit Hindernissen

Das Ende der vollständigen axillären Lymphknotendissektion

Update Onkologie